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Abstract
Background—Kidney transplant recipients, like other patients with chronic kidney disease 
(CKD), experience excess risk of cardiovascular disease (CVD) and elevated total homocysteine 
(tHcy) concentrations. Observational studies of patients with CKD suggest increased 
homocysteine is a risk factor for CVD. The impact of lowering total homocysteine (tHcy) levels in 
kidney transplant recipients is unknown.
Methods and Results—In a double-blind controlled trial, we randomized 4110 stable kidney 
transplant recipients to a multivitamin that included either a high dose (n=2056) or low dose 
(n=2054) of folic acid, vitamin B6, and vitamin B12 to determine whether decreasing tHcy 
concentrations reduced the rate of the primary composite arteriosclerotic CVD outcome 
(myocardial infarction, stroke, CVD death, resuscitated sudden death, coronary artery or renal 
artery revascularization, lower extremity arterial disease, carotid endarterectomy or angioplasty, or 
abdominal aortic aneurysm repair). Mean follow-up was 4.0 years. Treatment with the high dose 
multivitamin reduced homocysteine but did not reduce the rates of the primary outcome (n= 547 
total events; hazards ratio [95% confidence interval] = 0.99 [0.84–1.17]), or secondary outcomes 
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of all-cause mortality (n=431 deaths; 1.04 [0.86–1.26]) or dialysis-dependent kidney failure 
(n=343 events; 1.15 [0.93–1.43]) compared to the low dose multivitamin.
Conclusions—Treatment with a high dose folic acid, B6, and B12 multivitamin in kidney 
transplant recipients did not reduce a composite cardiovascular disease outcome, all-cause 
mortality, or dialysis-dependent kidney failure despite significant reduction in homocysteine level.
Keywords
cardiovascular disease risk factors; mortality; clinical trials; kidney
Introduction
Homozygous genetic disorders
1–3 resulting in marked elevations of plasma homocysteine 
(total homocysteine concentrations, 100–500 µmol/L), a sulfur amino acid by-product of 
methionine metabolism, are clearly associated with atherothrombotic events early in life.
4 
Total homocysteine (tHcy)-lowering treatment appears to reduce the incidence of these 
outcomes among such patients.
4,5 In addition, pooled data from prospective observational 
studies have suggested that mild to moderate hyperhomocysteinemia (tHcy levels, 12–99 
µmol/L)
6
 may also be a significant risk factor for arteriosclerotic cardiovascular disease 
(CVD) among the general population.
7
Longitudinal investigations of persons with chronic kidney disease (CKD) without kidney 
failure have demonstrated a relationship between higher levels of total homocysteine and 
CVD risk. Typically, the greatest relative risk was confined to persons with tHcy 
concentrations in the uppermost distribution. {
8,9 Whether mild to moderate 
hyperhomocysteinemia is a direct cause of arteriosclerotic outcomes in these CKD 
populations, or only a surrogate for clinical CVD, remains unresolved. Although a 
substantial number of randomized controlled clinical trials of tHcy-lowering treatment have 
been undertaken to evaluate efficacy for reducing CVD events among different patient 
populations at high risk for atherothrombotic sequelae,
10,11 including persons with 
CKD,
12–16 none has revealed a significant decrease in CVD outcomes.
10–16 Kidney 
transplant recipients are considered to have CKD, irrespective of glomerular filtration rate 
(GFR) or presence or absence of markers of kidney damage.
17
 Although there remains great 
heterogeneity among causes of CKD, many of the complications of CKD in kidney 
transplant recipients are similar to those experienced by persons with CKD of their native 
kidneys.
18
 In particular, kidney transplant recipients experience a high rate of both incident 
and recurrent CVD, {Bostom, 1999 #783;Friedman, 2002 #1240} and an excess prevalence 
of hyperhomocysteinemia despite the fortification of cereal grain flour with folic acid—a 
major determinant of plasma homocysteine concentrations.
8,9 Importantly, these patients are 
not treated routinely with supplemental folic acid but unlike patients with kidney failure 
treated by dialysis, it is possible to “normalize” their tHcy concentrations with combined 
folic acid, vitamin B12, and vitamin B6 treatment.
8,9
We conducted the Folic Acid for Vascular Outcome Reduction in Transplantation 
(FAVORIT) trial in clinically stable kidney transplant recipients.
19
 The primary objective 
was to determine whether decreasing tHcy levels with a multivitamin containing high doses 
Bostom et al. Page 3













of folic acid, vitamin B6, and vitamin B12 would reduce their risk of CVD outcomes 
compared to treatment with a “low-dose” multivitamin devoid of folic acid and with 
estimated average requirement amounts of vitamins B6 and B12.
Methods
Trial design
Details of the study design are published elsewhere.
19
 Briefly, the study was a multi-center 
double-blind randomized controlled clinical trial conducted to determine whether lowering 
homocysteine levels by vitamin therapy reduced the rate of pooled arteriosclerotic CVD 
outcomes. The trial received approval from the Institutional Review or Ethics boards of all 
30 clinical sites. Written informed consent was obtained from all participants.
Study Participants
Men and women aged 35 to 75 years and who were at least 6 months post-kidney transplant 
were screened for eligibility. Key entry criteria were stable kidney function (estimated 
creatinine clearance
20
 (Ccr) ≥ 30 mL/min through July 7, 2005; after which the cut point for 
women was ≥ 25 mL/min) and elevated homocysteine (≥ 11 µmol/L for women; ≥ 12 
µmol/L for men). Race and ethnicity were determined through self-report using categories as 
defined in the National Institutes of Health Policy on Reporting Race and Ethnicity Data.
21
Intervention
Participants were randomized to receive either a standard multivitamin with a high dose of 
folic acid (5.0 mg), vitamin B6 (pyridoxine; 50 mg) and vitamin B12 (cyanocobalamin; 1.0 
mg) or a multivitamin with a low dose of vitamin B6 (1.4 mg) and vitamin B12 (2.0 µg) and 
no folic acid. Both multivitamins were formulated similar in appearance and odor to 
facilitate blinding. Adherence was assessed by annual pill count and semi-annual self-report.
Baseline and Follow-up
The trial enrolled study participants from August 2002 through January 2007. Follow-up 
contacts occurred every six months through January 31, 2010 to obtain study related 
outcomes through June 24, 2009. Central laboratory methods for tHcy and creatinine 
determinations have been described.
22
 Due to resource limitations, baseline and follow-up 
tHcy analyses are reported on a convenience sample of 143 participants who were among the 
first participants enrolled. Glomerular filtration rate (eGFR) is estimated using the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
23
Outcomes
The primary outcome was pooled incident or recurrent CVD comprised of (1) CVD death, 
(2) myocardial infarction, (3) resuscitated sudden death, (4) stroke, (5) coronary artery 
revascularization, (6) lower extremity revascularization or amputation above the ankle for 
severe arterial disease, (7) carotid endarterectomy or angioplasty, (8) abdominal aortic 
aneurysm repair, or (9) renal artery revascularization. The first four components of the 
primary outcome noted above were centrally reviewed and adjudicated by the Clinical 
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Endpoints Committee (CEC); the remaining outcomes were identified through medical 
record abstraction. The CEC also reviewed records for unstable angina cases and urgent 
coronary revascularization procedures in search of myocardial infarctions that were not 
identified by the clinical site staff. Details of the outcome definitions are reported in the 
appendix.
Secondary outcomes were all-cause mortality, dialysis-dependent kidney failure, individual 
and meaningful combinations of components of the primary outcome, and the number of 
these that occur.
Statistical Issues
A sample size of 4,000 with an average of 5 years of follow-up was estimated to provide 
83% power to detect a 19% treatment effect and 87% power to detect a 20% treatment 
effect. Additional details on sample size estimates and power calculations are provided 
elsewhere.
19
Randomization by permuted block, stratified by clinical site, was performed through the data 
management system. Since the need for emergency unblinding was expected to be low, 
unblinding codes were stored securely at the DCC, accessible only to authorized staff.
In addition to having primary and secondary outcomes, we pre-specified primary and 
secondary analysis strategies. The fundamental analysis plan included using Kaplan-Meier 
methods and comparing unadjusted treatment effects with proportional hazards models 
stratified by country, using proportional hazards models to adjust for other variables (age 
group, race, sex, smoking, systolic blood pressure, diabetes status, LDL, CKD stage based 
on estimated GFR
23
 and country), and performing analogous subgroup analyses by age 
group, sex, race, diabetes status, and baseline tHcy level.
24
 Due to the limited ability of 
vitamins to normalize elevated tHcy levels in dialysis-dependent kidney failure patients, the 
primary analysis strategy invoked censoring at 3-months following return to chronic dialysis 
for the CVD and mortality outcomes. The secondary analysis strategy based on intention-to-
treat (ITT) principles was performed for all interim and final analyses. By design, the 
primary analysis of the secondary outcome of dialysis-dependent kidney failure is ITT. All 
computations were performed using SAS®, version 9.1 (SAS Institute, Cary, NC).
The Data and Safety Monitoring Board (DSMB) planned two interim efficacy analyses at 
accrual of 33% and 67% of the expected number of events. To provide flexibility in the 
number of interim analyses, a Lan-DeMets boundary
25
 was used as a stopping rule. 
Conditional power analyses
26,27 were also planned at these time points.
Results
Participant Characteristics
Participant flow is summarized in Figure 1; baseline data were presented previously.
22 
Briefly, 7,273 patients were screened, of whom 2,056 and 2,054 were randomized to high 
dose and low dose multivitamins, respectively; 34% did not meet eligibility cut points for 
tHcy and Ccr; and, 9% were not enrolled for other reasons. Baseline characteristics (Table 1) 
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were well-balanced between treatment groups overall and within country. Approximately 
78% of participants had CKD stage 3T or 4T (68% stage 3T, 10% stage 4T), and 20% 
reported a CVD history at baseline.
Follow-up and Early Termination
Follow-up ranged from 0 to 82 months yielding a mean of 4.0 ± 1.5 years. Complete follow-
up through June 24, 2009 was available for 2,788 participants, 493 participants were 
deceased, 822 had incomplete follow-up, and 7 participants had no follow-up. Slightly more 
participants in the high dose group withdrew consent during the study (198 high dose, 171 
low dose; P=0.16); lack of interest in continuing participation and health-related reasons or 
side effects were the most frequently cited reasons for withdrawal.
Interim analyses were performed at four points (proportion of total expected events): May 
2007 (0.31), April 2008 (0.43, conditional power only), May 2009 (0.60) and June 2009 
(0.60). The DSMB considered the fourth interim analysis on June 24, 2009 and 
recommended an early and orderly closeout of the study since it had “conclusively answered 
its original hypothesis”. Conditional power{Lan, 1988 #845} at information time 0.60 was 
0.19 (80% CI: 0.03 – 0.56) assuming the study design effect for the remainder of the trial 
and 0.004 (80% CI: 0.000 – 0.052) assuming that the trend observed to date continued for 
the duration of the study. The sponsor accepted this recommendation and closeout 
preparations commenced immediately. Final telephone contacts or clinic visits were 
conducted from June 25, 2009 through January 31, 2010.
Adherence, tHcy-Lowering and Blinding
Based on pill count, 84% of participants took at least 75% of the expected number of study 
multivitamins; 5% took less than 75% of the expected vitamins, and adherence could not be 
assessed for 11%. Adherence based on pill count was balanced between the treatment 
groups and consistent with self-reported adherence. The high dose multivitamin was 
effective in lowering tHcy. Based on a sample of 143 participants, the mean 4-year change 
from baseline tHcy was −4.6 µmol/L (SD=4.5, N=72) in the high dose group in comparison 
to −0.2 (SD=5.1, N=71; P<0.0001) in the low dose group, resulting in 4-year mean tHcy 
levels (µmol/L) of 11.8 (SD=3.8) and 15.9 (SD=5.5), respectively. Blinding was successful; 
49% of participants and 49% of study coordinators provided incorrect guesses for treatment 
assignment.
CVD, Mortality and Kidney Failure Outcomes
A total of 547 pooled CVD events are included in the primary (censored) analysis. 
Treatment groups did not differ significantly in occurrence of post-randomization CVD 
"(269-H, 278-L, P=0.93), all-cause mortality (217-H, 214-L, P=0.67), or dialysis-dependent 
kidney failure (181-H, 162-L, P=0.19) outcomes. (Table 2) As shown in Figure 2, no trends 
in event rates over 6 years were suggested for either the primary CVD outcome or all-cause 
mortality. A trend for more frequent return to dialysis-dependent kidney failure in the high 
dose group was not statistically significant (P=0.20). Adjustment for country, age group, 
race, sex, smoking, systolic blood pressure, diabetes status, LDL and CKD stage had little 
impact on the estimated effects. The hazard ratios (95% confidence interval) were: CVD 
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primary outcome 1.02 (0.85–1.22), all-cause mortality 0.99 (0.81, 1.22), and dialysis-
dependent kidney failure 0.90 (0.71, 1.14).
Analyses of the primary and secondary outcomes by subgroups also failed to demonstrate a 
statistically significant treatment effect. (Figure 3)
In the primary analyses, 37 CVD outcomes and 62 deaths were censored for occurring more 
than 3 months after dialysis-dependent kidney failure. Importantly, all intention-to-treat 
analyses yielded results very similar to the primary analyses with censoring at 3-months 
post-return to chronic dialysis. The ITT analysis for the pooled primary CVD outcome (290-
H, 294-L, P=0.91) was not statistically significant. For all-cause mortality, the ITT analysis 
included an additional 34 deaths in the high dose group and 28 deaths in the low dose group, 
and did not appreciably modify the survival curves (P=0.50).
Adverse Events
During follow-up, 62% of the participants were hospitalized at least once (1,272-H, 1,294-L, 
P=0.46) and accrued a total of 7,996 hospitalizations (3,933-H, 4,063-L). There were no 
statistically significant differences in discharge diagnosis (based on major ICD-9CM 
groupings) by treatment group. Disease of the circulatory system was the most prevalent 
discharge diagnosis grouping (1,934-H, 1,958-L) reported across all hospitalizations. 
Participant-reported multivitamin side effects also did not differ by treatment group. Among 
the high dose group, 269 participants reported side effects in comparison to 263 participants 
receiving the low dose multivitamin (P=0.32). Gastrointestinal disturbance was the side 
effect most often reported (121-H, 114-L, P=0.69).
Discussion
Among stable kidney transplant recipients with increased levels of homocysteine and 
reduced kidney function, treatment with a multivitamin containing a high dose of vitamin 
B6, vitamin B12 and folic acid did not reduce cardiovascular disease compared to a 
multivitamin with low doses of these ingredients. The high dose multivitamin also did not 
reduce all-cause mortality or onset of dialysis-dependent kidney failure. The lack of a 
beneficial effect on these outcomes was observed despite a significant reduction in tHcy in a 
sample of the high dose group. The frequency of adverse events did not differ by treatment 
group assignment.
Our findings may have applicability to the broader population of persons with CKD. Over 
three-fourths of our study participants had estimated GFR <60 ml/min/1.73m2 (CKD stage 
3T or 4T). As is the case for persons with CKD of their native kidneys, the risk of CVD in 
kidney transplant recipients is increased compared to the general population. Levels of tHcy 
in the patients with CKD vary according to the level of GFR, ranging from >25 µmol/L in 
kidney failure treated by dialysis to 10–25 µmol/L for earlier stages of CKD, and higher 
doses of B vitamins than those provided in cereal grain fortification are required to lower 
homocysteine levels to the range observed in the upper quartile of the general population. 
Our findings in kidney transplant recipients are in accord with two clinical trials of patients 
with CKD stage 5 (eGFR of < 15 ml/min/1.73 m2 or dialysis),
12
 or CKD stages 4 and 5 
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(eGFR of <30 ml/min/1.73 m2 or dialysis),
13
 and a secondary analysis of HOPE-2 study 
participants with (primarily) CKD stage 3 (eGFR of 30–59 ml/min/1.73 m2).
14
 Despite 
sustained ~ 4.0 to 8.5 micromolar reductions in tHcy achieved by these trials comparing 
active to “placebo” treatment, no decrease in CVD event or mortality rates was 
observed.
12–14
The lack of a beneficial effect of homocysteine lowering that we observed in kidney 
transplant recipients can be added to the largely negative findings of a substantial number of 
clinical trials in a wide range of patient populations.
28–35 Those studies effectively rule out 
the possibility of large effects on risk of coronary heart disease, stroke, and all-cause 
mortality as the pooled risk ratio for major cardiovascular disease events in those studies was 
1.02 (95% CI, 0.98–1.06).
10
 However, our trial shares a few limitations with these studies. 
Although the high dose multivitamin significantly reduced tHcy levels, mean values 
remained somewhat elevated. Importantly, the B-vitamin pathway for reducing tHcy may not 
be the optimal one for reducing CVD risk. Also, the duration of follow-up may not have 
been sufficient to identify a lagged impact on modification of CVD risk.
The lack of deleterious effects of homocysteine-lowering treatment on any of the major 
primary or secondary outcomes studied in FAVORIT is also concordant with results from 
trials of CKD and non-CKD populations.
10–14 In particular, previously reported trials of 
CKD patients,
12
 found no evidence of increased overall mortality, fatal or non-fatal cancer 
incidence, or progression to dialysis-dependent kidney failure associated with any of the 
high dose folic acid-based homocysteine-lowering regimens studied, relative to placebo 
treatment. Moreover, the absence of an increased hazard ratio for dialysis-dependent kidney 
failure in the high-dose group, despite 343 total events, is important given limited findings of 
a higher rate of decline in renal function observed among participants on B-vitamin therapy 
in the much smaller Diabetic Intervention with Vitamins to Improve Nephropathy trial.
36
Why have clinical trials of homocysteine–lowering uniformly failed to show a beneficial 
effect on CVD despite strong evidence for a beneficial effect seen in patients with marked 
hyperhomocysteinemia due to cystathionine beta synthetase (CBS) deficiency, whose risk 
for CVD is reduced by 90% with treatment,
4–5 and in view of the association of elevated 
tHcy levels with CVD seen in epidemiological studies?
37–42 It is likely that this is related to 
the marked difference in tHcy levels seen in patients with CBS deficiency, whose levels even 
after treatment remain above 100 µmol/L,5 in comparison with the levels more typically in 
the ranges of 12 – 25 µmol/L seen among patients in the observational studies. At these 
lower levels, it appears that the tHcy levels are a surrogate for other factors associated with 
increased CVD risk rather than a directly causative factor.
In conclusion, treatment of stable kidney transplant recipients with a multivitamin 
containing a high dose folic acid, B6, and B12 lowers tHcy levels relative to standard 
multivitamin supplementation and in many cases to normal levels, but does not reduce CVD 
outcomes, or total mortality in this patient population. Our findings add to the growing body 
of evidence from clinical trials of the failure of homocysteine lowering to reduce CVD, 
stroke and all-cause mortality in a wide range of patient populations.
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Kaplan-Meier analyses for (A) Primary CVD, (B) All-cause mortality, and (C) Dialysis-
dependent kidney failure outcomes
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Hazard ratios for treatment group comparisons from primary and secondary outcome 
subgroup analyses
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Table 1








Age --- yr 52 ± 9.4 52 ± 9.4 52 ± 9.5
Female sex --- no. (%) 1528 (37.2) 767 (37.3) 761 (37.0)
Non-white race --- no. (%) 945 (23.5) 477 (23.7) 468 (23.3)
Location --- no. (%)
  Brazil 612 (14.9) 307 (14.9) 305 (14.8)
  Canada 498 (12.1) 249 (12.1) 249 (12.1)
  United States 3000 (73.0) 1500 (73.0) 1500 (73.0)
Graft Vintage --- yr 5 ± 5.0 6 ± 5.1 5 ± 5.0
History of CVD --- no. (%) 820 (20.0) 406 (19.8) 414 (20.3)
History of diabetes --- no. (%) 1663 (40.5) 813 (39.6) 850 (41.5)
Prevalent hypertension --- no. (%) 3778 (92.0) 1879 (91.5) 1899 (92.5)
Body Mass Index --- kg/m2 29 ± 6.2 29 ± 6.2 29 ± 6.3
Current smoker --- no. (%) 451 (11.1) 230 (11.3) 221 (10.9)
Total Cholesterol --- mmol/L 4.8 ± 1.1 4.8 ± 1.2 4.8 ± 1.1
High-density lipoprotein cholesterol --- mmol/L 1.2 ± 0.4 1.2 ± 0.4 1.2 ± 0.4
Calculated or direct low-density lipoprotein cholesterol --- mmol/L 2.6 ± 0.9 2.6 ± 0.9 2.6 ± 0.9
Triglycerides --- mmol/L 2.2 ± 2.1 2.3 ± 2.5 2.2 ± 1.6
Screening homocysteine --- µmol/L 16.4 ± 1.3 16.4 ± 1.3 16.4 ± 1.3
  Female 16.8 ± 1.3 17.0 ± 1.3 16.7 ± 1.3
  Male 15.6 ± 1.3 15.3 ± 1.3 15.8 ± 1.3
Screening creatinine, mol/L 144.3 ± 42.1 145.0 ± 42.5 143.6 ± 41.6
Screening (eGFR, mL/min per 1.73 m2)* 48.8 ± 16.2 48.5 ± 15.9 49.0 ± 16.5
CKD Stage, n (%)*
  Stage 1T (eGFR 90 mL/min per 1.73 m2) 69 (1.7) 28 (1.4) 41 (2.0)
  Stage 2T (eGFR 60–89 mL/min per 1.73 m2) 819 (20.4) 405 (20.1) 414 (20.6)
  Stage 3T (eGFR 30–59 mL/min per 1.73 m2) 2738 (68.1) 1380 (68.7) 1358 (67.5)
  Stage 4T (eGFR 15–29 mL/min per 1.73 m2) 394 (9.8) 197 (9.8) 197 (9.8)
  Stage 5T (eGFR 15 mL/min per 1.73 m2) 1 (0.0) 0 (0.0) 1 (0.0)
*
Based on CKD-EPI eGFR formula{Levey, 2009 #1533}
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